Immunic Inc has appointed Michael A. Panzara as chief medical officer to lead the late-stage biotech’s development organisation, including clinical development, medical affairs and regulatory affairs. Dr Panzara brings 25 years of experience in neurology and in advancing therapies through development and regulatory approval. At Sanofi Genzyme, he oversaw the global regulatory approvals of multiple sclerosis drugs Lemtrada and Aubagio and at Biogen he managed the late-stage portfolio of MS products.
Most recently Dr Panzara was CMO of Neurvati Neurosciences. He has an MD from Stanford University School of Medicine and completed his neurology training at Massachusetts General Hospital. Immunic is advancing vidofludimus calcium for relapsed MS through the clinical readout of Phase 3 trials.
Immunic made the announcement on 28 April 2026.
Copyright 2026 Evernow Publishing Ltd.